RELEVANCE OF USING OF MICRODOSE COMBINED ORAL CONTRACEPTIVES IN A 24/4 REGIMEN IN YOUNG WOMEN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents data on the specific features of reproductive health and hormonal contraception perception in today’s adolescents and youth and provides a rationale for the use microdose combined oral contraceptives (COCs) in a 24/4 regimen in sexually active young people, which ensures the correction of the rhythm and pattern of menstruations and the leveling off of autonomous vital dysfunctions, the status of the breast, the prevention of ovarian cysts and genital endometriosis. Particular attention is given to COCs that contain metafolin, an active folic acid metabolite, which is involved in the provision of adequate hemostasis on menstrual days and in the correction of anemia and which is essential for the prevention of congenital malformations of the fetal neural tube.

Full Text

Restricted Access

About the authors

Elena Vitaljevna Uvarova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: elena-uvarova@yandex.ru
MD, Professor 117977, Russia, Moscow, Ac. Oparina str. 4

References

  1. Итоговый Отчет Выборочного обследования репродуктивного здоровья населения Российской Федерации (ВОРЗ). М.; 2012. 58 с
  2. Уварова E.B. Проблемы подростков и молодежи в аспекте демографической и социальной безопасности России. Репродуктивное здоровье детей и подростков. 2010; 6: 16-31
  3. Государственный доклад Министерства здравоохранения и социального развития РФ от 17 ноября 2011 г. “О положении детей в Российской Федерации” (2010 год)
  4. Молодежь России 2010. Статистический сборник/ЮНИСЕФ, Росстат РФ. М.: ИИЦ Статистика России; 2010. 166 с
  5. Информационное письмо Минздравсоцразвития России №15-2/10/2- 6334 от 30 июня 2011 г
  6. Доклад о состоянии здоровья населения и организации здравоохранения по итогам деятельности органов исполнительной власти субъектов РФ за 2013 год. М.: МЗ РФ; 2014.
  7. Баранов А.А. Состояние здоровье детей в Российской Федерации. Педиатрия. Журнал им. Г.Н. Сперанского. 2012; 91(3): 9-14.
  8. Кузнецова И.В. Девочка-подросток как пациент. Эндокринная гинекология физиологического пубертата: оптимальный минимум коррекции. Информационныйбюллетень. М.:StatusPraesens;2014. 20с.
  9. Куликов А.М. Анемия у подростков. Terra medica nova. 2009; 3: 20-3.
  10. Тарасова И.С., Чернов В.М., Красильнива М.В. Железодефицитные состояния у подростков: частотные характеристики, клинические проявления и возможные причины. Гематология и трансфузиология. 2006; 3: 32-7.
  11. Доброхотова Ю.Э., Корсунская И.М., Джобава Э.М., Рагимова З.Э. Андрогензависимая дермопатия как проявление синдрома гиперандрогении: методы коррекции. Гинекология. 2006; 8(5): 11-3.
  12. Кузнецова И.В. Комплексная терапия андрогензависимых дермопатий у девушек-подростков. Русский медицинский журнал. 2008; 1: 28-30.
  13. Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussell J., Stewart F., Stewart G.K., Kowal D., Guest F. et al., eds. Contraceptive technology. 17th ed. New York: Irvington Publishers; 1998: 779-844.
  14. Shvarts S., Besinque K., Atkinson R., Gill M.A. New advances in contraception. California Pharmacist Insights. 2001; November: 11-22.
  15. Прилепская В.Н. Защитные и лечебные аспекты современной гормональной контрацепции. Эффективная фармакотерапия. Акушерство и гинекология. 2011; 2: 88-90.
  16. Rosenberg M.J., Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol. 1998; 179: 577-82.
  17. Clinical Effectiveness Unit. Contraceptive choices for young people. London: Faculty of Sexual & Reproductive Healthcare; 2010 March. 26 p.
  18. Dinger J., Minh T.D., Buttmann N., Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 2011; 117(1): 33-40.
  19. Willis S.A., Kuehl TJ, Spiekerman A.M., Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006; 74(2): 100-3.
  20. Klipping C, Duljkers I., Trummer D., Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008; 78(1): 16-25.
  21. Guilbert E., Boroditsky R., Black A., Kives S., Leboeuf M., Mirosh M. et al.; Society of Obstetricians and Gynaecologists of Canada. Canadian consensus guideline on continuous and extended hormonal contraception, 2007. J. Obstet. Gynaecol. Can. 2007; 29(7, Suppl.2): S1-32.
  22. Sulak P.J., Scow R.D., Preece C., Riggs M.W., Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 2000; 95(2): 261-6.
  23. Pietrzik K., Bailey L., Shane B. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2010; 49(8): 535-48.
  24. Simpson J.L., Bailey L.B., Pietrzik K., Shane B., Holzgreve W. Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I--Folate, Vitamin B12, Vitamin B6. J. Matern. Fetal Neonatal Med. 2010; 23(12): 1323-43.
  25. Lamers Y., Prinz-Langenohl R., Bramswig S., Pietrzik K. Red blood cell folate concentrations increase more after supplementation with [6S]-5- methyltetrahydrofolate than with folic acid in women of childbearing age. Am. J. Clin. Nutr. 2006; 84(1): 156-61.
  26. Brown J. Nutrition through the life cycle. 3rd ed. Belmont, CA: Thomson Wadsworth; 2008: 109-112.
  27. Северин Е.С., ред. Биохимия. Учебник. М.: ГЭОТАР-Медиа; 2003: 494- 6.
  28. Prinz-Langenohl R., Bramswig S., Tobolski O., Smulders Y.M., Smith D.E., Finglas P.M., Pietrzik K. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild- type 677C^T polymorphism of methylenetetrahydrofolate reductase. Br. J. Pharmacol. 2009; 158(8): 2014-21.
  29. Busby A., Abramsky L., Dolk H., Armstrong B.; Eurocat Folic Acid Working Group. Preventing neural tube defects in Europe: population based study. Br. Med. J. 2005; 330(7491): 574-5.
  30. Lumley J., Watson L., Watson M., Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst. Rev. 2001; (3): CD001056.
  31. National Collaborating Centre for Women’s and Children’s Health. Antenatal care: routine care for the healthy pregnant woman. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Mar. 56 p. (Clinical guideline; no. 62).
  32. von Stenglin A., Buchwald S., Bannemerschult R. Awareness and peri-concep- tional use of folic acid - results of a European study in women of childbearing age (abstract and oral presentation). Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl.1): 37-8.
  33. von Stenglin A., Buchwald S., Lynen R. Women’s awareness and use of folate supplements prior to and during pregnancy: a global perspective (abstract and poster). Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl.1): 111-2.
  34. De-Regil L.M., Fernandez-Gaxiola A.C., Dowswell T., Pena-Rosas J.P. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst. Rev. 2010; (10): CD007950.
  35. Centers for Disease Control and Prevention (CDC). Use of supplements containing folic acid among women of childbearing age-United States, 2007. MMWR Morb. Mortal. Wkly Rep. 2008; 57(1): 5-8.
  36. Verbiest S. Folic acid fortification: should oral contraceptives be next? PRO. MCN Am. J. Matern. Child Nurs. 2005; 30(4): 228.
  37. Diefenbach K., Trummer D., Ebert F., Lissy M., Rohde B., Blode H. Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration (abstract and poster). Eur. J. Contracept. Reprod. Health Care. 2010; 15(Suppl.1): 157-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies